A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
Stephen P. Mulligan(Royal North Shore Hospital), Bryone J. Kuss(Flinders Medical Centre), Paul Turner(University of Oxford), Rosemary Harrup(University of Tasmania), Maya Latimer(Georgetown University), Devinder Gill(Princess Alexandra Hospital), David Simpson(North Shore Hospital), William Renwick(The Royal Melbourne Hospital), Naomi Mackinlay(Royal North Shore Hospital), Melanie Sulda(Flinders Medical Centre), Campbell Tiley(Gosford Hospital), Leanne Berkahn(Auckland City Hospital), Paul Cortissos(Peter MacCallum Cancer Centre), Philip Campbell(Barwon Health), Gavin Cull(Sir Charles Gairdner Hospital), Marnie Collins(Peter MacCallum Cancer Centre), Giles Best(Flinders University)
Cited by 14
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
|American Journal of Hematology|2019|472